ArticleJournal of the Chinese Medical Association : JCMA2026
Biologics reduced infections in ankylosing spondylitis and psoriatic arthritis under immunosuppressants.
Article in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologic disease-modifying antirheumatic drugs (bDMARDs) alleviate inflammation but may have immunocompromising effects. Previous studies evaluating infection risks in spondyloarthritis (SpA) have yielded inconsistent conclusions. We investigated infection risk in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) receiving bDMARDs compared with that of those receiving only conventional synthetic disease-modifying antirheumatic drugs.
methodsUsing the database at Taipei Veterans General Hospital (from January 1, 2011, to September 30, 2018), we retrospectively identified eligible SpA patients and applied a two-step verification process to confirm serious infections requiring hospitalization. Time-to-event outcomes were analyzed using multivariable Cox regression adjusted for age, sex, comorbidities, and concomitant medications. Site-specific analyses characterized infection patterns.
resultsWe included 5568 patients with SpA (4,784 AS, 784 PsA), with a mean age of 42.1 years and male predominance (68.4%). bDMARD prescription was associated with a reduced risk of first serious infection in the overall SpA cohort (adjusted hazard ratio [aHR] = 0.247, p = 2.4782 × 10 -7 ), as well as in AS (aHR = 0.253, p = 4.73 × 10 -4 ) and PsA (aHR = 0.207, p = 6.69 × 10 -4 ). bDMARD prescription was also associated with significantly lower risks of skin and soft tissue infection in PsA (aHR = 0.252, p = 1.1905 × 10 -2 ) and pneumonia/gastrointestinal infections in SpA. Sulfasalazine (SSZ) was independently associated with an increased infection risk (aHR = 1.630, p = 2 .6276 × 10 Sulfasalazine 2 ); nonsteroidal anti-inflammatory drugs were associated with a reduced risk in AS.
conclusionAdjunctive bDMARD therapy was associated with a substantially reduced risk of serious infection in AS, PsA, and the overall SpA cohort, potentially because of effective systemic inflammation suppression in SpA and restoration of the skin barrier in PsA. The elevated risk associated with SSZ in AS may reflect channeling bias in refractory patients. Early and appropriate use of bDMARDs in SpA may achieve disease control without compromising immune defense against infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.